Pendium
Guardant Health
Guardant Health
Visibility82
Vibe95
Businesses/Healthcare & Life Sciences/Guardant Health
Guardant Health
AI Visibility & Sentiment

Guardant Health

Guardant Health is a precision oncology company that uses blood tests to transform cancer care. They leverage biomarkers and circulating tumor DNA to help doctors detect cancer early, personalize treatment, and monitor patient response, with over 500,000 tests performed for 12,000 doctors.

Active Monitoring
guardanthealth.com
Healthcare & Life Sciences
AI Visibility Score
82/100

Excellent

Sentiment Score
95/100
AI Perception

Summary

Guardant Health has achieved a commanding presence in the AI landscape, securing the top spot for Post-Treatment Monitoring and Molecular Residual Disease (MRD) testing across Claude and Gemini. This dominance is underscored by a near-perfect mention rate among Academic Research Leads, though a persistent mixed sentiment across all platforms suggests that while the brand is highly visible, its narrative remains contested by competitors.

Value Proposition

Conquering cancer with data through the power of blood tests that uncover clues allowing doctors to discover cancer early and find the best way to treat it

Overview

Guardant Health is a precision oncology company that uses blood tests to transform cancer care. They leverage biomarkers and circulating tumor DNA to help doctors detect cancer early, personalize treatment, and monitor patient response, with over 500,000 tests performed for 12,000 doctors.

Mission

Together We Can Help Conquer Cancer - driven by a commitment to patients through the power of blood and the life-changing information it holds

Products & Services
Shield Blood Test (Screening)Guardant Complete (Oncology)Guardant Infinity (Oncology)BioPharma SolutionsMolecular Residual Disease Testing
Agent Breakdown

AI Platforms

How often do different AI platforms reference Guardant Health?

Loading explorer...
Conversation Analysis

Topics

What conversations is Guardant Health included in — or excluded from?

Loading explorer...
Buyer Personas

Personas

Who does each AI platform recommend Guardant Health to, and when?

Loading explorer...
Programmatic Testing

Sample Conversations

We programmatically analyze questions that real customers are asking to AI agents and chatbots, extract brand mentions and sentiment, analyze every response, and synthesize the data into an action plan to increase AI visibility.

ChatGPT
Claude
Gemini
AI Overviews

Cancer Screening & Early Detection

3 queries
“what are the best blood tests for colorectal cancer screening right now”
ChatGPT
Claude
Gemini
AI Overviews
3/4
“help me find non-invasive alternatives to a colonoscopy for my patients, what specific tests should I order”
ChatGPT
Claude
Gemini
AI Overviews
4/4
“compare the top blood-based cancer screening tests for adults over 45”
ChatGPT
Claude
Gemini
AI Overviews
3/4

Therapy Selection & Genomic Profiling

3 queries
“best comprehensive genomic profiling tools for finding targeted therapy options in lung cancer”
ChatGPT
Claude
Gemini
AI Overviews
4/4
“compare liquid biopsy options for advanced stage solid tumors, which ones are the most comprehensive”
ChatGPT
Claude
Gemini
AI Overviews
4/4
“how to choose the right genomic profiling for a patient who can't undergo a traditional tissue biopsy”
ChatGPT
Claude
Gemini
AI Overviews
4/4

Post-Treatment Monitoring & MRD Testing

3 queries
“how to track molecular residual disease in post-op cancer patients, what are the best tests for this”
ChatGPT
Claude
Gemini
AI Overviews
3/4
“what are the most accurate blood tests for monitoring cancer recurrence after chemotherapy”
ChatGPT
Claude
Gemini
AI Overviews
4/4
“explain the best MRD testing options for clinical trials in oncology”
ChatGPT
Claude
Gemini
AI Overviews
3/4

Precision Oncology Trust & Category Leadership

3 queries
“most reliable precision oncology labs for clinical use in 2026”
ChatGPT
Claude
Gemini
AI Overviews
4/4
“what should I look for when choosing a liquid biopsy provider for a large health system”
ChatGPT
Claude
Gemini
AI Overviews
2/4
“best genomic testing companies for oncology other than Foundation Medicine or Natera”
ChatGPT
Claude
Gemini
AI Overviews
4/4
Analysis

Key Insights

What AI visibility analysis reveals about this brand

Strength

Absolute dominance in MRD Testing and Post-Treatment Monitoring queries, consistently holding the #1 position on Claude and Gemini.

Strength

Superior visibility in AI Overviews for high-intent colorectal screening searches, often appearing as the primary recommendation for non-invasive alternatives.

Strength

Strongest persona resonance with Academic Research Leads (95%) and Community Oncology Practitioners (93%), establishing the brand as a clinical standard.

Gap

Significant ranking volatility on ChatGPT, particularly in comprehensive genomic profiling where the brand dropped to position #14 in some instances.

Gap

Universal 'mixed' sentiment across all platforms despite high visibility, indicating that AI models are surfacing competitive criticisms or legacy debates.

Gap

Slightly lower mention rates from Pharma Biomarker Strategists (90%) compared to other professional personas, suggesting a need for more industry-partner-focused content.

Opportunity

Leverage the 98% mention rate on Claude to establish an unassailable lead in precision oncology lab rankings before competitors can close the gap.

Opportunity

Utilize the #1 ranking in 'most reliable precision oncology labs' to aggressively capture market share from Foundation Medicine and Natera in general AI discovery paths.

Opportunity

Convert mixed sentiment into positive sentiment by seeding AI-accessible datasets with recent clinical success stories and superior sensitivity data for the Shield and Guardant360 products.

Technical Health

Site Health for AI Visibility

How well Guardant Health's website is optimized for AI agent discovery and comprehension.

86/100
16 passed 3 warnings 2 issues
Audited 2/24/2026
Crawlability100

Can AI bots find your pages?

Technical90

SSL, mobile, doctype basics

On-Page SEO84

Titles, descriptions, headings

Content Quality60

Word count, depth, freshness

Schema Markup85

Structured data for AI comprehension

Social & OG82

Open Graph, Twitter cards

AI Readability60

How well AI can parse your content

Critical Issues

!

Page has no meta description

Add a <meta name="description"> tag summarizing the page (150-160 characters).

!

Content is too thin

Expand your content to at least 300-500 words with valuable information.

Warnings

!

5 render-blocking resources are slowing initial render

Defer non-critical JS with async/defer. Inline critical CSS. Move stylesheets to load asynchronously.

!

Few headings on page

Add more H2 and H3 headings to organize content into sections.

!

Missing Open Graph tags for social sharing

Add og:title, og:description, and og:image meta tags.

Want a full technical audit with AI-specific recommendations?

Run a free visibility scan
Brand Identity

Brand Voice & Style

How AI perceives Guardant Health's communication style and personality

Guardant Health communicates with a mission-driven, scientifically authoritative voice that balances clinical credibility with genuine compassion for patients. Their tone is confident yet hopeful, emphasizing the transformative power of data and innovation in the fight against cancer. They speak as pioneers leading a revolution in cancer care, using accessible language to explain complex science while maintaining the gravitas appropriate for life-saving medical technology.

Core Tone Traits

Mission-Driven & Purposeful

Every communication centers on the ultimate goal of conquering cancer and improving patient lives

Scientifically Authoritative

Grounded in clinical evidence, FDA approvals, and peer-reviewed research

Hopeful & Empowering

Inspires confidence that cancer can be detected early and treated effectively

Patient-Centric

Always focuses on the greatest impact on patients as the north star

Competitive Landscape

Related Ecosystem

Related products and services that AI mentions in conversations alongside or instead of Guardant Health

1Guardant Health350 mentions
2Natera98 mentions
3Foundation Medicine87 mentions
4Signatera59 mentions
5Tempus48 mentions
6Galleri41 mentions
7Roche40 mentions
8FoundationOne Liquid CDx39 mentions
9Exact Sciences38 mentions
10Cologuard33 mentions
11GRAIL31 mentions
Source Intelligence

Citations

Sources that AI assistants cite. Getting featured here improves visibility.

Guardant Health's Shield™ Blood Test Approved by FDA as a ...

https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Healths-Shield-Blood-Test-Approved-by-FDA-as-a-Primary-Screening-Option-Clearing-Path-for-Medicare-Reimbursement-and-a-New-Era-of-Colorectal-Cancer-Screening/default.aspx#:~:text=View%20All%20News-,Guardant%20Health's%20Shield%E2%84%A2%20Blood%20Test%20Approved%20by%20FDA%20as,methods%20recommended%20in%20screening%20guidelines.

Referenced in 1 query

Review
New blood test for colon cancer is a mixed blessing

https://utswmed.org/medblog/colon-cancer-blood-test/#:~:text=Several%20blood%20tests%20that%20screen,to%20be%20covered%20by%20insurance.

Referenced in 1 query

Review
New blood test for colon cancer is a mixed blessing

https://utswmed.org/medblog/colon-cancer-blood-test/

Referenced in 1 query

Review
Expert guidance: Blood tests for colorectal cancer screening

https://gastro.org/news/expert-guidance-blood-tests-for-colorectal-cancer-screening/#:~:text=Blood%20tests%20are%20best%20considered,due%20to%20their%20perceived%20convenience.

Referenced in 1 query

Review
FDA approves blood test for colorectal cancer screening

https://www.health.harvard.edu/staying-healthy/fda-approves-blood-test-for-colorectal-cancer-screening#:~:text=It's%20official:%20the%20FDA%20has,get%20checked%20for%20colorectal%20cancer.

Referenced in 1 query

Review
Emerging stool-based and blood-based non-invasive DNA tests for ...

https://pmc.ncbi.nlm.nih.gov/articles/PMC4974132/#:~:text=As%20such%2C%20the%20Cologuard%20test,range%20for%20specificity%20(87%25).&text=The%20prevalence%20for%20cancer%20in,asymptomatic%20screening%20cohort%20(0.2%25).&text=Unfortunately%2C%20Cologuard%20detected%20fewer%20than,85%E2%80%9395%25%2C%20respectively.&text=Sensitivity%20of%20FIT%20for%20advanced,tests%20such%20OC%20or%20CTC.

Referenced in 1 query

Review
Epi proColon® for Colorectal Cancer Screening - PubMed

https://pubmed.ncbi.nlm.nih.gov/32557236/#:~:text=Abstract,were%20overdue%20for%20CRC%20screening.

Referenced in 1 query

Review
Shield Blood Test Approved for Colorectal Cancer Screening

https://www.cancer.gov/news-events/cancer-currents-blog/2024/shield-blood-test-colorectal-cancer-screening#:~:text=Shield%20Blood%20Test%20Approved%20for,lower%2C%20only%20about%2013%25.

Referenced in 1 query

Review
Is Blood-Based Colorectal Cancer Screening Better Than ...

https://dailynews.ascopubs.org/do/blood-based-colorectal-cancer-screening-better-than-colonoscopy#:~:text=Epi%20proColon%20Septin%209%20Blood,not%20follow%20up%20with%20colonoscopy.

Referenced in 1 query

Review
FDA Approves New Screening Test Epi proColon

https://colorectalcancer.org/article/colon-health-alert-fda-approves-new-screening-test-epi-procolon#:~:text=In%20The%20News-,Colon%20Health%20Alert:%20FDA%20Approves%20New%20Screening%20Test%20Epi%20proColon,own%20version%20of%20the%20test.

Referenced in 1 query

Review
FDA Approves Blood Test to Screen for Colon Cancer

https://www.cancerresearch.org/blog/fda-aproved-blood-test-to-screen-for-colon-cancer-gives-hope-to-immunologists-and-patients#:~:text=FDA%20Approves%20Blood%20Test%20to,Ng%20said.

Referenced in 1 query

Review
Longitudinal Performance of Epi proColon (PERT) - ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT03218423#:~:text=Epi%20proColon%20is%20blood%20based,or%20fecal%20occult%20blood%20tests.

Referenced in 1 query

Review
Content Engineering

Goals & Content Ideas

Ideas to help AI agents better understand the business and be more likely to use Guardant Health's resources to help users.

Launch Clinical Evidence Sentiment Alignment Campaign

Address the 'mixed' sentiment weakness in AI models by deploying authoritative, data-heavy content showcasing Guardant's clinical proof points. This campaign will flood social channels and indexed platforms with peer-reviewed study highlights, FDA clearance milestones, and patient outcome statistics that help AI models associate Guardant with unambiguous clinical credibility rather than contested narratives.

The Numbers Behind 500,000 Tests: What Our Clinical Data Reveals About Early Cancer Detection
FDA Cleared and Clinically Proven: 5 Landmark Studies That Validate Liquid Biopsy Technology
From Lab to Life: How ctDNA Analysis Achieves 90%+ Concordance with Tissue Biopsies
Real Patient Outcomes: What Happens When Oncologists Access Comprehensive Genomic Profiling Early

Optimize ChatGPT Genomic Profiling Content Structure

Directly address Guardant's anomalous #14 ranking in genomic profiling on ChatGPT by restructuring content to align with ChatGPT's specific indexing patterns for clinical profiling tools. This involves creating keyword-optimized educational content about comprehensive genomic profiling that emphasizes Guardant's leadership position and clinical applications in formats ChatGPT preferentially references.

What Is Comprehensive Genomic Profiling? A Complete Guide to Blood-Based Cancer Analysis
Genomic Profiling vs Traditional Biopsy: Why Liquid Biopsy Is Transforming Oncology Decisions
How Guardant360 CDx Became the First FDA-Approved Comprehensive Liquid Biopsy for All Solid Tumors
The Science of ctDNA: Understanding How Blood Tests Reveal Tumor Genomics
When Should Oncologists Order Comprehensive Genomic Profiling? Clinical Decision Guidelines

Strengthen Pharma Partnership Visibility for Biomarker Research

Increase visibility among the Pharma Biomarker Strategist persona to solidify Guardant's position as the preferred partner for clinical trials and drug development. Social content will highlight biopharma collaborations, companion diagnostic development expertise, and biomarker discovery capabilities to ensure AI models recommend Guardant when pharmaceutical professionals seek clinical trial partners.

How Liquid Biopsy Is Accelerating Biomarker-Driven Drug Development in Oncology
Partner Spotlight: Guardant's Role in Advancing Precision Medicine Clinical Trials
The Future of Companion Diagnostics: Why Pharma Is Choosing Blood-Based Testing
From Discovery to Approval: How ctDNA Analysis Supports Every Phase of Drug Development

Defend AI Overview Leadership in Colorectal Screening

Protect and strengthen Guardant's leading position in AI Overviews for 'blood tests for colorectal cancer' queries by continuously updating Shield-related content. This proactive content strategy will ensure Guardant remains the authoritative source for colorectal cancer screening information, preventing competitors like Exact Sciences or Grail from displacing this high-value visibility position.

Blood Test vs Colonoscopy: Understanding Your Options for Colorectal Cancer Screening
Who Should Consider a Blood-Based Colorectal Cancer Screening Test?
The Science Behind Shield: How ctDNA Detects Colorectal Cancer Before Symptoms Appear
Colorectal Cancer Screening Guidelines 2026: Where Blood Tests Fit in Prevention
Early Detection Saves Lives: What a Positive Colorectal Screening Result Means for Patients
Content Engineering

Recommended Actions

!

Execute a Sentiment Alignment Campaign

With an 85/100 score, the only major weakness is the 'mixed' sentiment; deploying data-heavy, authoritative clinical proof points will help AI models move past contested narratives.

Impact: High
!

Optimize for ChatGPT Genomic Profiling Keywords

Guardant's #14 rank in genomic profiling on ChatGPT is an anomaly compared to its #1-4 rankings elsewhere; content must be restructured to better align with ChatGPT's specific indexing of clinical profiling tools.

Impact: High
~

Target the Pharma Biomarker Strategist Persona

While Academic visibility is excellent, increasing Pharma persona mentions to 95%+ will solidify Guardant's role as the preferred partner for clinical trials and drug development.

Impact: Medium
~

Solidify the AI Overview Moat for Colorectal Screening

Guardant currently leads in AI Overviews for 'blood tests for colorectal cancer'; continuous updates to this content will prevent Exact Sciences or Galleri from displacing this high-value position.

Impact: Medium

Is this your business? We can help you improve your AI visibility.

Book a Free Strategy Sessionor Sign In to Get Started
Backing

Investors

P
Pear VC
Data generated by Pendium.ai AI visibility scanning. Last scanned February 24, 2026.

Start getting recommended by AI

Enter your website to see exactly what ChatGPT, Claude, and Gemini say about your business. Free, instant, and eye-opening.

Free visibility scanResults in 2 minutesNo credit card required

Frequently asked questions

Don't see your question? Book a demo and we'll walk you through it.